Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma

Must have received: standard therapy

disease progression after standard therapy, intolerable to standard therapy, or for whom no standard therapy exists

Must have received: standard therapy

had received at least one prior line of standard therapy and were relapsed after or refractory to the standard therapy

Cannot have received: QPCTL inhibitor

Prior treated with other QPCTL...inhibitors

Cannot have received: CD47 inhibitor

Prior treated with other...CD47...inhibitors

Cannot have received: SIRPA inhibitor

Prior treated with other...SIRPα inhibitors

Cannot have received: anti-tumor therapy

Anti-tumor therapy (chemotherapy, immunotherapy, targeted therapy, biologic therapy, or other anti-tumor therapy) within 28 days or 5 half-lives, whichever is shorter prior to first dose of study treatment

Cannot have received: antitumor steroid therapy

Received antitumor steroid therapy within 7 days prior to the first study treatment administration

Cannot have received: allogeneic stem cell transplantation

Exception: within 3 months prior to first receiving study treatment

Previous allogeneic stem cell transplantation...within 3 months prior to first receiving study treatment

Cannot have received: autologous stem cell transplantation

Exception: within 3 months prior to first receiving study treatment

Previous...autologous stem cell transplantation within 3 months prior to first receiving study treatment